Guangdong Marubi Biotechnology Co (603983) — Working Capital to Net Assets Ratio
Guangdong Marubi Biotechnology Co (603983) has a Working Capital to Net Assets ratio of 32.5% as of March 2026. Working capital of CN¥1.14 Billion (current assets of CN¥2.31 Billion minus current liabilities of CN¥1.18 Billion) is measured against net assets of CN¥3.49 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Guangdong Marubi Biotechnology Co (603983) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Guangdong Marubi Biotechnology Co Working Capital to Net Assets (2011–2025)
This chart shows how Guangdong Marubi Biotechnology Co's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 32.5%, reflecting working capital of CN¥1.14 Billion against net assets of CN¥3.49 Billion CNY. Check Guangdong Marubi Biotechnology Co (603983) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Guangdong Marubi Biotechnology Co (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Guangdong Marubi Biotechnology Co from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 603983 market cap.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 30.6% | CN¥1.04 Billion | CN¥3.39 Billion | CN¥2.24 Billion | CN¥1.20 Billion | ▼ -8.8 pp |
| 2024 | 39.4% | CN¥1.36 Billion | CN¥3.45 Billion | CN¥2.95 Billion | CN¥1.60 Billion | ▼ -5.1 pp |
| 2023 | 44.5% | CN¥1.52 Billion | CN¥3.42 Billion | CN¥2.53 Billion | CN¥1.01 Billion | ▼ -3.8 pp |
| 2022 | 48.2% | CN¥1.57 Billion | CN¥3.25 Billion | CN¥2.24 Billion | CN¥668.47 Million | ▲ +3.9 pp |
| 2021 | 44.3% | CN¥1.40 Billion | CN¥3.16 Billion | CN¥1.98 Billion | CN¥576.55 Million | ▼ -18.9 pp |
| 2020 | 63.2% | CN¥1.90 Billion | CN¥3.00 Billion | CN¥2.68 Billion | CN¥786.64 Million | ▼ -26.3 pp |
| 2019 | 89.5% | CN¥2.39 Billion | CN¥2.67 Billion | CN¥3.13 Billion | CN¥740.04 Million | ▲ +11.2 pp |
| 2018 | 78.2% | CN¥1.08 Billion | CN¥1.38 Billion | CN¥1.79 Billion | CN¥709.39 Million | ▲ +7.3 pp |
| 2017 | 71.0% | CN¥681.31 Million | CN¥959.96 Million | CN¥1.30 Billion | CN¥619.49 Million | ▲ +9.3 pp |
| 2016 | 61.6% | CN¥510.42 Million | CN¥828.09 Million | CN¥1.15 Billion | CN¥634.71 Million | ▲ +10.4 pp |
| 2015 | 51.3% | CN¥367.14 Million | CN¥715.92 Million | CN¥1.02 Billion | CN¥649.88 Million | ▲ +9.9 pp |
| 2014 | 41.4% | CN¥250.44 Million | CN¥604.48 Million | CN¥847.93 Million | CN¥597.49 Million | ▲ +5.4 pp |
| 2013 | 36.1% | CN¥163.46 Million | CN¥453.11 Million | CN¥649.60 Million | CN¥486.14 Million | ▲ +30.1 pp |
| 2012 | 5.9% | CN¥13.97 Million | CN¥234.87 Million | CN¥483.79 Million | CN¥469.82 Million | ▲ +9.7 pp |
| 2011 | -3.7% | CN¥-5.48 Million | CN¥148.02 Million | CN¥443.46 Million | CN¥448.94 Million | — |